...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I|[sol]|II trial
【24h】

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I|[sol]|II trial

机译：I | [sol] | II期临床试验的结果：复发性神经胶质瘤患者的肿瘤裂解物脉冲树突状细胞接种疫苗可引发免疫反应。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In this Phase I/II trial, the patient's peripheral blood dendritic cells were pulsed with an autologous tumour lysate of the glioma. Seven patients with glioblastoma and three patients with anaplastic glioma, ranging in age from 20 to 69 years, participated in this study. The mean numbers of vaccinations of tumour lysate-pulsed dendritic cells were 3.7 times intradermally close to a cervical lymph node, and 3.2 times intratumorally via an Ommaya reservoir. The percentage of CD56-positive cells in the peripheral blood lymphocytes increased after immunisation. There were two minor responses and four no-change cases evaluated by radiological findings. Dendritic cell vaccination elicited T-cell-mediated antitumour activity, as evaluated by the ELISPOT assay after vaccination in two of five tested patients. Three patients showed delayed-type hypersensitivity reactivity to the autologous tumour lysate, two of these had a minor clinical response, and two had an increased ELISPOT result. Intratumoral CD4+ and CD8+ T-cell infiltration was detected in two patients who underwent reoperation after vaccination. This study demonstrated the safety and antitumour effects of autologous tumour lysate-pulsed dendritic cell therapy for patients with malignant glioma.
机译：在该I / II期试验中，患者的外周血树突状细胞被神经胶质瘤的自体肿瘤裂解物脉冲。年龄在20至69岁之间的7例胶质母细胞瘤患者和3例间变性胶质瘤患者参加了这项研究。肿瘤溶解物脉冲树突状细胞的平均接种次数是真皮内接近颈部淋巴结的3.7倍，肿瘤内通过Ommaya水库的3.2倍。免疫后外周血淋巴细胞中CD56阳性细胞的百分比增加。根据放射学检查结果评估有两个轻微反应和四个不变病例。树突状细胞疫苗接种可诱导T细胞介导的抗肿瘤活性，如疫苗接种后五分之二的患者通过ELISPOT分析进行评估。 3例患者对自体肿瘤溶解产物显示迟发型超敏反应，其中2例临床反应较轻，2例ELISPOT结果升高。在两名接种疫苗后再次手术的患者中检测到肿瘤内CD4 +和CD8 + T细胞浸润。这项研究证明了自体肿瘤裂解物脉冲树突状细胞疗法对恶性神经胶质瘤患者的安全性和抗肿瘤作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号